D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Due to climate change, many parts of Europe are facing longer and more intense mosquito seasons, with mosquito-borne ...

The speed and effectiveness of an organisation’s response are crucial, writes Richard Ford, CTO at Integrity360.

A hypocaloric diet, defined by reduced calorie intake below daily energy expenditure, promotes weight loss and improves ...

What is guidance in finance? If you've been trading stocks for a while, it's almost guaranteed that you've come across company guidance, even if you didn't know what it was called. These are the ...

Watch in this video as we ask the 2025 Drama League nominees about advice they'd share with young performers with an eye on Broadway. Hear from Bernadette Peters, Jonathan Groff, Megan Hilty ...

On July 17, 2024, the U.S. Patent and Trademark Office (“USPTO”) published its 2024 Guidance Update on Patent Subject‑Matter Eligibility, Including on Artificial Intelligence (the “2024 ...

Platform: Web, Windows, macOS, Android, iPhone Plan: Free, Subscription Type: Logo maker, logo generator Today's Best Deals Adobe Creative Cloud Express - Free Adobe Creative Cloud Express - Premium ...

The vector ratings for the Golf Ball Hot List encompass five distinct areas based on tester performance assessments. Here is a guide to the five vector ratings: Feel: This vector scale reflects a ...

Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, “ICON continues to navigate dynamic clinical development market ...

ICON (NASDAQ:ICLR) stock fell 8% early Tuesday after it issued financial guidance for 2025. The clinical research organization said that it expects to report 2025 revenue of $8.05B to $8.650B ...

Full year 2025 adjusted earnings per share * guidance in the range of $13.00 - $15.00; midpoint of $14.00, flat over full year 2024 adjusted earnings per share guidance midpoint.